High-Dose Inactivated Influenza Vaccine Linked to Lower Rates of Hospitalization in HF
There is decreased risk for hospitalization in patients with heart failure who receive a high-dose inactivated influenza vaccine.
High-dose inactivated influenza vaccine (HD-IIV) is associated with reduced rates of hospitalizations related to laboratory-confirmed influenza, cardiorespiratory disease, cardiovascular (CV) disease, and heart failure (HF) in patients with HF, according to a study in Circulation: Heart Failure.
The findings are from a prespecified exploratory analysis of the DANFLU-2 trial conducted in Denmark during 3 consecutive influenza seasons, from 2022 to 2023 through 2024 to 2025.
- The trial included individuals aged 65 years and older who were randomly assigned 1:1 to receive HD-IIV or standard-dose inactivated influenza vaccine (SD-IIV).
No direct quotes available in the text.
Author's summary: High-dose influenza vaccine reduces hospitalization rates in heart failure patients.